Rather, wild-type (w.t.)DC-RA fully protect against peanut-induced anaphylaxis in vivo by driving the differentiation of LAG3+CD49b+Maf+Foxp3− Treg—unlike w.t. DC-RA, IL-27-/- DC-RA are of no therapeutic benefit (74). The gene discussed is MAF; the disease is rheumatoid arthritis.